Form for disclosing material information

Date	27.04.2022
Name of the Listed Company	Gulf Pharmaceutical Industries (JULPHAR)
The Material Information	Gulf Pharmaceutical Industries (Julphar) has entered into a subscription agreement with Quantum Genomics to subscribe new ordinary shares of Quantum Genomics share capital for an aggregate subscription price of USD 2 million. Julphar is strengthening the partnership with Quantum Genomics in their cooperation to market Firibastat in the Middle East, Africa, some member countries of the Commonwealth of Independent States and Turkey.
The expected effect of material information on the financial position and results of the company's business and operations	Financial Investment of USD 2 million.
The financial period in which the financial impact will appear	Q2 2022

The Name of the Authorized Signatory	Rayan Omer
--------------------------------------	------------

Designation	Board Secretary
Signature and Date	27/04/2022
Company's Seal	Shamaceut/cer ta
Sulphar E	